SCHEMBL707201

SCHEMBL707201

O=C(O)[C@H]1CC[C@H](OC(F)(F)F)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
PLG P00747 1/20 0.39
PLAT P00750 1/20 0.39
GABRP O00591 2/20 0.38
GABRD O14764 2/20 0.38
GABRA1 P14867 2/20 0.38
GABRB1 P18505 2/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRA5 P31644 2/20 0.38
GABRA3 P34903 2/20 0.38
GABRA2 P47869 2/20 0.38
GABRB2 P47870 2/20 0.38
GABRA4 P48169 2/20 0.38
GABRE P78334 2/20 0.38
GABRA6 Q16445 2/20 0.38
GABRG1 Q8N1C3 2/20 0.38
GABRG3 Q99928 2/20 0.38
GABRQ Q9UN88 2/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL707202 1.00 LMNA (0.39) LMNAPLGPLATGABRPGABRD
SCHEMBL7532313 0.83
SCHEMBL16708925 0.80 OAT (0.35) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL16699710 0.80 OAT (0.35) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL16699712 0.80 OAT (0.35) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL25474802 0.78 LMNA (0.39) LMNAPLGPLATGABRPGABRD
SCHEMBL9680450 0.78 LMNA (0.39) LMNAPLGPLATGABRPGABRD
SCHEMBL25490288 0.78 LMNA (0.39) LMNAPLGPLATGABRPGABRD
SCHEMBL17729826 0.78
SCHEMBL2051876 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007143847-A1 SPIROTROPANE COMPOUNDS VIROCHEM PHARMA INC. (CA) 2007-12-21 WO claimed
US-8124613-B2 Spirotropane compounds VIROCHEM PHARMA INC. (CA) 2012-02-28 US disclosed
US-20110105546-A1 SPIROTROPANE COMPOUNDS VIROCHEM PHARMA INC. (CA) 2011-05-05 US disclosed
EP-0688752-B1 Trifluoro-2-(trans-4-substituted cyclohexyl) ethylenes and process for their production ASAHI GLASS CO LTD (JP) 1999-01-13 EP disclosed
US-5621147-A LIQUID CRYSTAL INTERMEDIATES ASAHI GLASS COMPANY LTD. (JP) 1997-04-15 US disclosed
EP-0688752-A1 Trifluoro-2-(trans-4-substituted cyclohexyl) ethylenes and process for their production ASAHI GLASS COMPANY LTD. (JP) 1995-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105546-A1 SPIROTROPANE COMPOUNDS CCR5, CXCR1, CXCR2 LMNA 2735/4885PLG 2909/4885PLAT 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.